FDA's Avastin decision: into the minds of regulators
This article was originally published in Scrip
Executive Summary
The FDA last week laid out its big decision on Avastin’s breast cancer indication in a 69-page ruling. The document had two somewhat distinct sections: known-knowns and known-unknowns – to borrow the peculiar vernacular of Donald Rumsfeld, former US defence secretary.